Patents matching “anti-”

WO 2024052517

USAGE MÉDICAL D'ANTICORPS ANTI-CCR8 ET PROGRAMME DE DOSAGE

BAYER AG [DE] · Granted Mar 14, 2024 · Expires Mar 9, 2044

US 11926670

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Mar 12, 2024 · Expires Mar 7, 2044

US 11925685

DNA antibody constructs encoding anti-ZIKV envelope antibodies

Inovio Pharmaceuticals, Inc. · Granted Mar 12, 2024 · Expires Mar 7, 2044

US 11926668

Anti-PD-1 antibodies for treatment of lung cancer

REGENERON PHARMACEUTICALS, INC. · Granted Mar 12, 2024 · Expires Mar 7, 2044

US 11919965

Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Mar 5, 2024 · Expires Feb 29, 2044

US 11918640

Methods of preparing anti-human papillomavirus antigen T cells

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 5, 2024 · Expires Feb 29, 2044

US 11912780

Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies

Actinium Phamaceuticals, Inc. · Granted Feb 27, 2024 · Expires Feb 22, 2044

US 11911464

Anti-parasitic immunological compositions

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Feb 27, 2024 · Expires Feb 22, 2044

US 11912762

Method of treating osteoarthritis by administering an anti-connexin 43 antibody

The Board of Regents of the University of Texas System · Granted Feb 27, 2024 · Expires Feb 22, 2044

US 11903936

Anti-malarial agents

The Board of Regents of the University of Texas System · Granted Feb 20, 2024 · Expires Feb 15, 2044

US 11897933

Anti-KRAS-G12D T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 13, 2024 · Expires Feb 8, 2044

US 11897945

Methods of treating allergy using anti-Bet v 1 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Feb 13, 2024 · Expires Feb 8, 2044

US 11890353

Anti-polyethylene glycol (PEG) antibody mouse model for rigorous assessment of PEG-based therapies

Northwestern University · Granted Feb 6, 2024 · Expires Feb 1, 2044

CA 3259391

POLYTHÉRAPIE ANTI-GARP-TGF-β1/PD-1

ABBVIE BIOTHERAPEUTICS INC [US] · Granted Feb 1, 2024 · Expires Jan 27, 2044

US 11884740

Anti-CD20 antibody compositions

TG Therapeutics, Inc. · Granted Jan 30, 2024 · Expires Jan 25, 2044

US 11884657

PI-kinase inhibitors with anti-infective activity

The Regents of the University of California · Granted Jan 30, 2024 · Expires Jan 25, 2044

US 11883433

Chimeric antigen receptor comprising anti-mesothelin scFv, and use thereof

CELLENGENE INC. · Granted Jan 30, 2024 · Expires Jan 25, 2044

US 11879017

Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 23, 2024 · Expires Jan 18, 2044

US 11866488

Compositions comprising an anti-metallothionein antibody and a pancreatic cell targeting moiety

UNIVERSITY OF CONNECTICUT · Granted Jan 9, 2024 · Expires Jan 4, 2044

US 11866502

Anti-FGFR2 antibodies and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Jan 9, 2024 · Expires Jan 4, 2044

US 11859007

Humanized anti-CD73 antibodies

Corvus Pharmaceuticals, Inc. · Granted Jan 2, 2024 · Expires Dec 28, 2043

US 11859000

Anti-CCR8 antibodies and uses thereof

VACCINEX, INC. · Granted Jan 2, 2024 · Expires Dec 28, 2043

US 11857701

Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications

The Board of Regents of the University of Texas System · Granted Jan 2, 2024 · Expires Dec 28, 2043

US 11851498

Anti-CD276 antibodies (B7H3)

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 26, 2023 · Expires Dec 21, 2043